These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

653 related items for PubMed ID: 3319120

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
    Gawel M, Riopelle R, Libman I, Bouchard S.
    Adv Neurol; 1987; 45():535-8. PubMed ID: 3548263
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
    Hutton JT, Morris JL, Bush DF, Smith ME, Liss CL, Reines S.
    Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
    [Abstract] [Full Text] [Related]

  • 5. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
    Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D, Esterlitz J.
    Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Low-dosage treatment in de novo patients with Parkinson's disease: a prospective study.
    van der Drift JH.
    Adv Neurol; 1987 Nov; 45():529-34. PubMed ID: 3825731
    [Abstract] [Full Text] [Related]

  • 9. The Sydney multicentre study of Parkinson's disease. The first 18 months.
    Hely MA, Morris JG, Rail D, O'Sullivan DJ, Williamson PM, Genge S, Reid WG, Broe GA.
    Med J Aust; 1987 Feb 16; 146(4):195-8. PubMed ID: 3553878
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
    Brannan T, Yahr MD.
    Ann Neurol; 1995 Jan 16; 37(1):95-8. PubMed ID: 7818264
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
    Peppe A, Dambrosia JM, Chase TN.
    Adv Neurol; 1993 Jan 16; 60():698-702. PubMed ID: 8420213
    [No Abstract] [Full Text] [Related]

  • 16. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
    Chaná P, Fierro A, Reyes-Parada M, Sáez-Briones P.
    Rev Med Chil; 2003 Jun 16; 131(6):623-31. PubMed ID: 12942590
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS, Kirby L, Kumar D, Cullen EI, Pratt RD, Hahne WA.
    Br J Clin Pharmacol; 2004 Nov 16; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [Abstract] [Full Text] [Related]

  • 19. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM, Hoey M, Kutt H, McDowell FH.
    Clin Neuropharmacol; 1988 Apr 16; 11(2):168-73. PubMed ID: 3378225
    [Abstract] [Full Text] [Related]

  • 20. [Bromocriptine in Parkinsonian syndromes. Results obtained in a group of patients treated for 8 months].
    Quattrini A, Paggi A, Del Pesce M, Di Bella P.
    Riv Patol Nerv Ment; 1978 Apr 16; 99(3):150-63. PubMed ID: 752907
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.